Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2009-05-22
2011-11-29
Canella, Karen (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S155100, C514S013300, C514S016100, C514S019200, C514S019300, C514S019400, C435S007230
Reexamination Certificate
active
08067000
ABSTRACT:
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
REFERENCES:
patent: 4190496 (1980-02-01), Rubenstein et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5082838 (1992-01-01), Naka et al.
patent: 5114918 (1992-05-01), Ishikawa et al.
patent: 5187195 (1993-02-01), Oohata et al.
patent: 5198548 (1993-03-01), Beylin et al.
patent: 5208243 (1993-05-01), Peglion et al.
patent: 5240910 (1993-08-01), Lam et al.
patent: 5248807 (1993-09-01), Fujimoto et al.
patent: 5270313 (1993-12-01), Burri et al.
patent: 5334598 (1994-08-01), Bagley et al.
patent: 5352659 (1994-10-01), Wakimasu et al.
patent: 5352800 (1994-10-01), Bills et al.
patent: 5382569 (1995-01-01), Cody et al.
patent: 5464853 (1995-11-01), Chan et al.
patent: 5550110 (1996-08-01), Cody et al.
patent: 5573762 (1996-11-01), Ferrara et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 6063911 (2000-05-01), Vournakis et al.
patent: 6673832 (2004-01-01), Davar
patent: 2067288 (1992-10-01), None
patent: 2071193 (1992-12-01), None
patent: 0 436 189 (1991-07-01), None
patent: 0 496 452 (1992-07-01), None
patent: 0 499 266 (1992-08-01), None
patent: 0 558 258 (1993-09-01), None
patent: 0 569 193 (1993-11-01), None
patent: 0 801 062 (1997-10-01), None
patent: 1 181555 (2008-12-01), None
patent: WO 91/02062 (1991-02-01), None
patent: WO 92/06180 (1992-04-01), None
patent: WO 92/20316 (1992-11-01), None
patent: WO 92/22635 (1992-12-01), None
patent: WO 93/14188 (1993-07-01), None
patent: WO 93/20221 (1993-10-01), None
patent: WO 94/27979 (1994-12-01), None
patent: WO 98/41206 (1998-09-01), None
patent: WO 00/36918 (2000-06-01), None
patent: WO 01/00198 (2001-01-01), None
Adner et al., 1994, “Human endothelin ETAreceptor antisense oligodeoxynucleotides inhibit endothelin-1 evoked vasoconstriction”, Eur. J. Pharm. 261:281-284.
Albino et al., 1991, “Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.” Cancer Res., 51 :4815.
Arai et al., 1990, “Cloning and expression of a cDNA encoding an endothelin receptor.”Nature, 348:730.
Bagnato et al., 2007, “Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.” Cell Tissues Organs 185:85-94.
Barber et al., 1996, “Chronic increases in blood flow upregulate endothelin-B receptors in arterial smooth muscle”, Am. J. Physiol. 270:H65-H71.
Battistini and Dussault, 1998, “Blocking of the endothelin system: the development of receptor antagonists”, Pul. Pharm. Therap. 11:97-112.
Becker et al., 1992, “Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation.” Oncogene, 7:2303.
Benigni et al., 1993, “A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression.” Kidney Int., 44:440.
Bird, 1988, “Single-chain antigen-binding proteins.” Science, 242:423.
Bolger et al., 1991, “Vascular reactivity, tissue levels, and binding sites for endothelin: a comparison in the spontaneously hypertensive and Wistar-Kyoto rats.” Can. J. Physiol. Pharmacol., 69: 406.
Brabant, et al., 1993, “E-cadherin: a differentiation marker in thyroid malignancies.” Cancer Research, 53: 4987.
Breu et al., 1996, “In vitro characterisation of Ro 46-8443, the first non-peptide antagonist selective for the endothelin ETB receptor.” FEBS Letters 383:37-41.
Breuer et al., 1993, “Detection of elevated C=Erbb-2 Oncoprotein in the serum and tissue in breast cancer.” Med. Chem. Res. 3:154-162.
Brooks et al., 1991, “Effect of nifedipine on cyclosporine A-induced nephrotoicity, urinary endothelin ecretion and renal endothelin receptor number.” Eur. J. Pharm. 194:115.
Calabresi P. and Chabner B. A., Goodman and Gilman The Pharmacological Basis of Therapeutics, Pergamon Press, 8thEdition, 1202-1204, Aug. 1990.
Calabresi P. and Chabner B. A., Goodman and Gilman The Pharmacological Basis of Therapeutics, Pergamon Press, 8th Edition, pp. 1209-1216, Aug. 1990.
Chan et al., 1998, “The discovery and structure-activity relationships of nonpeptide, low molecular weight antagonists selective for the endothelin ETBreceptor”, Bioorganic & Medicinal Chemistry 6:2301-2316.
Clozel et al., 1993, “Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist.” Nature 365:759-761.
D'Orléans-Juste et al., 1997, “DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors”, Molec. Cell. Biochem 172:199-211.
Daniel etal., 1997, “Tyrosine phosphorylation and cadherin/catenin function.” BioEssays, 19(10}: 883-891.
Davenport and Battistini, 2002, “Classification of endothelin receptors and antagonists in clinical development”, Clinical Science 103:1S-3S.
Doherty, 1992, “Endothelin: a new challenge.” J. Med. Chem., 35: 1493-1508.
Dorudi, et al., 1993, “E-cadherin epression in colorectal cancer. An immunocytochemical and in situ hybridization study.” American Journal of Pathology, 142:981-986.
Dotto et al., 1989, “Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment.” J. Cell Biol., 109:3115-3128.
Douglas, 1997, “Clinical development of endothelin receptor antagonists”, TIPS 18:408-412.
Eck et al., 1996, “Gene Based therapy,” in Pharmacological Basis of Therapeutics., Goodman & Gilman, Eds 77-101.
Fujimoto et al., 1992, “A novel non-peptide endothelin antagonist isolated from bayberry,Myrica cerifera.” FEBS Lett., 305:41-44.
Furchgott and Zawadski, 1980, “The obligatory role of endothelial cells in the relaation of arterial smooth muscle by acetylcholine.” Nature, 288:373-376.
Gamallo, et al., 1993, “Correlation of E-cadherin epression with differentiation grade and histological type in breast carcinoma.” American Journal of Pathology, 142:987-993.
Greenspan & Bona, 1993, “Idiotypes: structure and immunogenicity.” FASEB J., 751:437-444.
Halaban et al., 1992, “Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.” Oncogene, 7:2195-2206.
Halaban, 1991, “Growth factors and tyrosine protein kinases in normal and malignant melanocytes.” Cancer Metastasis Rev., 10:129-140.
Herren, et al., 1998, “Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases.” Mol. Biol. Cell., 9: 1589-601.
Hsu, et al., 1996, “Shifts in Cadherin Profiles Between Human Normal Melanocytes and Melanomas ” J. Investig. Dermatal. Symp. Proc., 1:188.
Hunt et al., 1991, “Structure Activity-Relationships of Monocyclic endothelin Analogs.” Biorganic and Medic. Chem. Lett., 1:33-38.
Imokawa, et al., 1992, “Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes.” J. Biol. Chem., 267;24675-80.
Imokawa, et al., 1996 “Signalling mechanisms of e
Jamal Sumayah
Schneider Robert J.
Canella Karen
Day Jones
New York University
LandOfFree
Cancer treatment with endothelin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatment with endothelin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment with endothelin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252735